Compare Ascendis Pharma A/S (ASND) vs Kraft Heinz Co (KHC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Kraft Heinz Co — how do they compare? Ascendis Pharma A/S trades at $265.85 (market cap $17.74B), while Kraft Heinz Co trades at $25.27 (market cap $29.47B). The key difference: Kraft Heinz Co is the larger of the two by market cap, and Kraft Heinz Co pays a 6.44% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | KHC | |
|---|---|---|
Market Cap | $17.74B | $29.47B |
Sector | Health | Consumer Staples |
52-Week High | $277.18 | $28.94 |
52-Week Low | $163.32 | $21.21 |
Enterprise Value | $18.11B | $46.51B |
Dividend Yield | — | 6.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Kraft Heinz (KHC) trades at $24.85, up 0.69% with bullish technical momentum including a golden cross formation. The company shows mixed fundamentals with strong cash flow generation ($4.46B operating cash flow in 2025) but negative profitability metrics (-23.05% net margin). Recent earnings beats and a 6.4% dividend yield provide support, while the company's global reorganization aims to accelerate growth. Technical indicators show bullish moving averages with neutral oscillators, trading near key resistance at $25.
KHC presents a value opportunity with attractive valuation (P/E 13.04, P/B 0.7) and high dividend yield, but faces significant profitability challenges. The stock's upside depends on successful execution of restructuring initiatives and margin improvement. Key risks include persistent negative earnings, competitive pressures, and execution missteps in the new operating structure. Analyst consensus remains cautious with only 11% buy ratings despite recent positive technical momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Kraft Heinz Co
In July 2015, Kraft merged with Heinz to create the third-largest food and beverage manufacturer in North America behind PepsiCo and Nestle and the fifth-largest player in the world. Beyond its namesake brands, the combined firm's portfolio includes Oscar Mayer, Velveeta, and Philadelphia. Outside North America, the firm's global reach includes a distribution network in Europe and emerging markets that drive around one fifth of its consolidated sales base, as its products are sold in more than 190 countries and territories.
Read more on KHC →
